Llwytho...
Tocilizumab in COVID‐19 interstitial pneumonia
BACKGROUND: Published reports on tocilizumab in COVID‐19 pneumonitis show conflicting results due to weak designs or heterogeneity in critical methodological issues. METHODS: This open‐label trial, structured according to Simon's optimal design, aims to identify factors predicting which patient...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Intern Med |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8013903/ https://ncbi.nlm.nih.gov/pubmed/33511686 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/joim.13231 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|